Reuters logo
BRIEF-Oncolytics Biotech announces first patient treated in Muk Eleven study
September 14, 2017 / 11:09 AM / 8 days ago

BRIEF-Oncolytics Biotech announces first patient treated in Muk Eleven study

Sept 14 (Reuters) - Oncolytics Biotech Inc:

* Oncolytics Biotech announces first patient treated in muk eleven study

* Oncolytics Biotech - once maximum tolerated dose has been identified with no associated safety issues, 10 additional patients will be enrolled at MTD

* Oncolytics Biotech Inc - preliminary data for Muk Eleven study expected to be available in Q1 2018 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below